Actually in the UK human rights law does not necessarily trump a statutory exemption. The 1998 Human Rights Act enables cases to be brought in accordance with ECHR in UK domestic courts, but in the end if statute conflicts with ECHR principles then statute takes precedence.
It is possible then to take cases to ECtHR. That’s true.
Article 10 is qualified, Article 6 is not.
If a statute conflicts with ECHR principles, section 3 of the Human Rights Act 1998 “requires courts to interpret both primary and subordinate legislation so that their provisions are compatible with the articles of the European Convention of Human Rights”. If such an interpretation is impossible, section 4 allows them to issue a declaration of incompatibility.
And then, of course, you can bring cases to Strasbourg.
Yes, article 10 is qualified, and the FOI interpretation of article 10 is also qualified (see Magyar Helsinki Bizottság v. Hungary, 18030/11).
Appeal of the National Institutes of Health’s (NIH’s) response to my FOIA request received:
Answer: in many many months or years?
Another ITP candidate? This interview with Dr Ronald DePinho of MD Anderson was published on 2 August 2024, 2 days ago: “Restoring TERT to attenuate ageing hallmarks”.
They have identified a small-molecule TERT (telomerase) promoter called “TAC” after screening 700,000 compounds, working with partners at Scripps Clinic. He reports really impressive improvements in a lot of the hallmarks of aging, working with mice. Notably, looks like this doesn’t increase cancer risk that much, here’s a quote:
“It is important to note that TAC increases TERT expression in the physiological range as opposed to the very high levels (approximately 10-fold higher) observed in cancer cells. Thus, we achieved our first goal of TERT restoration, increasing levels by 50 to 100 percent.”
Somebody with some clout should reach out to these folks and get them to submit to the ITP…
I don’t think Rick Miller is really convinced that telomeres affect lifespan much, but you should definitely try to persuade him and the rest of the team to test TAC.
https://www.nia.nih.gov/research/dab/interventions-testing-program-itp/application-instructions
Source: x.com
https://www.nia.nih.gov/research/dab/interventions-testing-program-itp/supported-interventions
Yes, I am excited by GLYNAC. It’ll either validate or condemn it. The others are brilliant as well. Excellent choices this year.
Trametinib Rapa! Awesome. I was going to submit for it again in 2025 if it didn’t make the cut. In 2023 I proposed Rapa + Trametinib + Lithium but was turned down.
FANTASTIC! It’ll settle the debate once and for all regarding deprenyl, sildenafil, and GlyNAC (hopefully in a positive way!).
See you in May 2028 for the results…
Finally, Deprenyl is being dusted off the shelves. I hope they dose it correctly in the ITP because I could see it because bad at high doses and good at low doses.
What’s weird is that I asked the Hungarian team behind all the previous deprenyl research and they were not even aware that it was going to be tested in the ITP… (they didn’t seem to be interested in the ITP either…)
The dose will be 5 ppm so 0.83 mg/kg/day. Starting age still TBD. The best results in the literature (mostly coming from that weird Hungarian lab) were obtained at 0.25 mg/kg three times per week but subcutaneously (source). According to ChatGPT and Perplexity, 0.25 mg sc ~ 2 mg oral. So 0.25 mg/kg 3x/week ~ 0.86 mg/kg/day. Exactly what the ITP chose! 
Yesss, Live long and prosper. See you in 2028.
Honestly, I’d rather get the results in 2029 or 2030. 
As a reminder, I sponsored selegiline / deprenyl on worms and it failed at 50 µM: Ora Biomedical Million Molecule Challenge Results - #155 by adssx
Is that too high? What would be the equivalent of 0.83 mg/kg/day in mice in C. elegans?
What would the human dose equivalent be of 0.86mk/kg per day? Forgive my inability to know how to convert rat doses.
Perplexity tells me about 5 mg/day: https://www.perplexity.ai/search/what-is-the-human-dose-equival-l6.d9zFKTYOWjtnS01_IaQ#0
Which is a lot. That’s the Parkinson’s dose. And there’s zero evidence that Parkinson’s patients on selegiline live longer or have any improvements other than symptomatic. People who use selegiline for “longevity” take about 1 mg/day (or 5 mg/week by cutting the 5 mg pill in four to use 1.25 mg/day, 4 days per week).
I wrote this article on Selegiline: Selegiline - Longevity Wiki
Great article. I occasionally check out Longevity Wiki and didn’t realize you wrote for it.
I agree that 5mg daily seems to be high for longevity. I have been taking 1.25mg per day on and off for around 7 years maybe, ever since I read about it in Life Extension magazine. I’m very interested in what more research ends up telling us here.
I only wrote that article, any one can write anything btw. And it seems that the project is dead.
Anyway, after writing this article I became less convinced about selegiline. Hopefully I’m wrong. Time will tell. I’ll wait to see the ITP results (or anything else convincing) before trying it…
I have to say it doesn’t look too compelling to me after reading it either. Might have a small benefit but I don’t think it will be anywhere close to Rapamycin or Acarbose level.
Yes, its rare that you see old research dusted off and restarted… seems worthwhile given what we know: Deprenyl - Anti-Aging Drug Proven Effective in Dogs
